Publication date: Mar 27, 2025
Alterity is continuing to advance a broader drug discovery platform targeting neurodegenerative diseases.
| Concepts | Keywords |
|---|---|
| Biotech | Alterity |
| Ceo | Ath434 |
| Disease | Clinical |
| Melbourne | Diseases |
| Drug | |
| Evaluate | |
| Label | |
| Msa | |
| Neurodegenerative | |
| Open | |
| Patient | |
| Phase | |
| Stage | |
| Trial | |
| Visit |
Semantics
| Type | Source | Name |
|---|---|---|
| drug | DRUGBANK | Isoxaflutole |
| drug | DRUGBANK | Iron |
| pathway | REACTOME | Neurodegenerative Diseases |
| disease | MESH | neurodegenerative diseases |
| disease | MESH | multiple system atrophy |
Original Article
(Visited 1 times, 1 visits today)